Cipla Ltd.'s consolidated net profit rose 30% year-on-year in the fourth quarter of the current financial year, beating analysts' estimates.
The drugmaker posted a consolidated bottom line of Rs 1,222 crore in the quarter-ended March, according to an exchange filing on Tuesday. That compares with the Rs 1,023-crore consensus estimate of analysts tracked by Bloomberg.
The company's revenue climbed 9% year-on-year to Rs 6,729.69 crore, whereas the earnings before interest, taxes, depreciation and amortisation increased by 17% to Rs 1,538 crore. The Ebitda margin expanded to 22.8% from 21.4%.
Cipla Q4 FY25 Highlights (Consolidated, YoY)
Revenue up 9.2% to Rs 6,729.69 crore versus Rs 6,163.24 crore (Estimate: Rs 6,704 crore).
Net profit up 30% to Rs 1,221.84 crore versus Rs 939.04 crore (Estimate: Rs 1,023 crore).
Ebitda up 17% to Rs 1,537.59 crore versus Rs 1,315.86 crore (Estimate: Rs 1,556 crore).
Margin at 22.8% versus 21.4% (Estimate: 23.2%).
Cipla's 'One India' business grew 8% year-on-year during the quarter. Branded prescription business continued to outpace the market growth in key chronic therapies, the drugmaker said, while adding that trade generics is back on growth trajectory and anchor brands of the company continued to grow bigger.
Notably, the One India business contributes 42% to overall revenue.
Among other geographies, North America contributes 29% to Cipla's overall topline. However, the revenue from the continent slipped 2% year-on-year to $221 million.
Shares of Cipla were trading 0.36% lower at Rs 1,506.10 apiece on the NSE, as compared to a 1.29% fall in the benchmark NSE Nifty 50.
Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.
